TY - JOUR
T1 - Trends in incidence, diagnosis, treatment and survival of hepatocellular carcinoma in a low-incidence country
T2 - Data from the Netherlands in the period 2009-2016
AU - Reinders, Margot T. M.
AU - van Meer, Suzanne
AU - Burgmans, Mark C.
AU - de Jong, Koert P.
AU - Klumpen, Heinz-Josef
AU - de Man, Robert A.
AU - Ramsoekh, D. (Sandjai)
AU - Sprengers, Dave
AU - Tjwa, Eric T. T. L.
AU - de Vos-Geelen, Judith
AU - van Erpecum, Karel J.
AU - van der Geest, Lydia G. M.
AU - Dutch Hepatocellular & Cholangiocarcinoma Group (DHCG)
N1 - Funding Information:
M.T.M.R. reports grants from Dutch Cancer Society ( KWF Kankerbestrijding ); received personal fees from Boston Scientific / BTG, United Kingdom ; received other fees from Quirem Medical B.V.; received nonfinancial support from Quirem Medical B.V. and Terumo , outside the submitted work. M.C.B. reports grants from ZonMW Programma Translationeel Onderzoek/Topsector LSH , Maag Lever Darm Stichting ; reports receiving nonfinancial support from Quirem Medical for HORA EST HCC study; grants from Covidien for HORA EST HCC study, outside the submitted work. H.J.K. reports receiving personal fees from IPSEN and SIRTEX, outside the submitted work. J.d.V.-G. reports grants and nonfinancial support from Servier , outside the submitted work. K.J.v.E. reports grants from Dutch Cancer Society ( KWF Kankerbestrijding ), outside the submitted work. All other authors report no conflict of interest.
Publisher Copyright:
© 2020 Elsevier Ltd
PY - 2020/9
Y1 - 2020/9
N2 - Objective: Evaluation of the trends in incidence, diagnostics, treatment and survival of patients with hepatocellular carcinoma (HCC) in the Netherlands.Method: Data regarding incidence, diagnostics, primary treatment and survival of patients with HCC in the period 2009-2016 were obtained from the Netherlands Cancer Registry. Trends in incidence, diagnostics, various treatment modalities (except liver transplantation, due to inaccurate data) and regional treatment preferences were analysed. Survival was evaluated using Kaplan-Meier curves and multivariable Cox proportional hazard regression modelling.Results: In the period of 2009-2016, 3838 patients were diagnosed with HCC. A distinct decrease in the percentage of patients who underwent tumour biopsy was observed (from 51% in 2009-2010 to 42% in 2015-2016). Percentage of patients who underwent cancer treatment increased markedly (from 49% in 2009-2010 to 57% in 2015-2016), mainly because of an increasing use of resection and ablation. The number of hospitals where resections were performed or sorafenib treatment prescribed decreased slightly. The number of hospitals sporadically (Conclusion: From 2009 to 2016, patients with hepatocellular carcinoma more often received cancer treatment and their survival improved. There were significant differences in types of treatment between various regions. (C) 2020 Elsevier Ltd. All rights reserved.
AB - Objective: Evaluation of the trends in incidence, diagnostics, treatment and survival of patients with hepatocellular carcinoma (HCC) in the Netherlands.Method: Data regarding incidence, diagnostics, primary treatment and survival of patients with HCC in the period 2009-2016 were obtained from the Netherlands Cancer Registry. Trends in incidence, diagnostics, various treatment modalities (except liver transplantation, due to inaccurate data) and regional treatment preferences were analysed. Survival was evaluated using Kaplan-Meier curves and multivariable Cox proportional hazard regression modelling.Results: In the period of 2009-2016, 3838 patients were diagnosed with HCC. A distinct decrease in the percentage of patients who underwent tumour biopsy was observed (from 51% in 2009-2010 to 42% in 2015-2016). Percentage of patients who underwent cancer treatment increased markedly (from 49% in 2009-2010 to 57% in 2015-2016), mainly because of an increasing use of resection and ablation. The number of hospitals where resections were performed or sorafenib treatment prescribed decreased slightly. The number of hospitals sporadically (Conclusion: From 2009 to 2016, patients with hepatocellular carcinoma more often received cancer treatment and their survival improved. There were significant differences in types of treatment between various regions. (C) 2020 Elsevier Ltd. All rights reserved.
KW - Hepatocellular carcinoma
KW - Liver cancer
KW - Cancer diagnostics
KW - Cancer treatment
KW - Survival
KW - MANAGEMENT
KW - VOLUME
U2 - 10.1016/j.ejca.2020.07.008
DO - 10.1016/j.ejca.2020.07.008
M3 - Article
C2 - 32799035
SN - 0959-8049
VL - 137
SP - 214
EP - 223
JO - European Journal of Cancer
JF - European Journal of Cancer
ER -